Adamis Pharma announces patent litigation regarding its higher dose Naloxone injection
Adamis announced that on May 20, 2019, it received notice that it had been named and served as a defendant in a lawsuit filed by kaléo in the U.S. District Court for the District of Delaware regarding Adamis’ higher dose naloxone injection product candidate for treatment of opioid overdose. May 21, 2019